case_images: PMC11282559_01
case_images: An image of the tumor located on the patient's back.
case_images: 10.1177_2050313X241254732-fig1.jpg
case_images: PMC11282559_01_10.1177_2050313X241254732-fig1.jpg
case_images: fig1-2050313X241254732
case_images: A 36-year-old white woman former smoker (2-pack-year) on ustekinumab (initiated in 2020) with a history of HS, inflammatory ileal CD, type 2 diabetes mellitus, and adverse events in response to adalimumab (initiated in 2012, discontinued in 2013 due to drug induced lupus), infliximab (initiated in 2011, discontinued in 2012 due to joint pain), and vedolizumab (initiated and discontinued in 2017 due to bacteremia), presented with a solitary 6 x 2.5 cm2 mass on her back (Figure 1) in February of 2022.